ETEvgenia Leonidovna Trisvetova

Evgenia Leonidovna Trisvetova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evgenia Leonidovna Trisvetova has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical significance of intracardiac anatomical variations structures and minor anomalies (literature review)

    by Eu. L. Trisvetova

    Wide application of intravital methods of visualization of internal cardiac structures in clinical practice allows identifying anatomical features of the organ structure and pathological intracardiac formations. Due to heterogeneity and variability of intracardiac formations found in a normal heart, difficulties arise in differential diagnostics with pathological formations (thrombus, tumor) and decision on further tactics. Normal intracardiac structures are usually not accompanied by pathological clinical manifestations, they are discovered during life by chance or during autopsy, however, occasionally their topographic and morphological variants cause cardiac arrhythmias or thromboembolism. To prevent false diagnoses in the development of pathological symptoms, other structural heart diseases (ischemic heart disease, cardiomyopathy, myocarditis, etc.) are excluded. The main available method for studying intracardiac structures and minor cardiac anomalies is transthoracic echocardiography, the results of which are supplemented by transesophageal examination, if necessary – computed tomography and magnetic resonance imaging. In case of arrhythmic syndrome, an electrophysiological study is performed to establish the causes of arrhythmia. Multimodal visualization using modern research methods, electrophysiological study and knowledge of the topography of anatomical variants of internal structures and minor anomalies of the heart will allow timely differential diagnostics and planning of further treatment or observation tactics.

  • Open Access

    Risk factors of ventricular arrhythmias in non-syndromic mitral valve prolapse

    by E. L. Trisvetova

    Non-syndromic mitral valve prolapse (MVP) is a common disease. In most cases, its benign course is noted, however, a connection between MVP and ventricular arrhythmias is reported, as well as sudden cardiac death. Clinical signs (chest pain, syncope/lipotymia, mid-systolic click), results of instrumental studies (electrocardiographic, echocardiographic, magnetic resonance imaging) allow us to identify known ("old") risk factors and new phenomena encountered in rhythm and conduction disturbances during MVP. Signs of "arrhythmic" MVP, often detected in young women, include prolapse of thickened both mitral valve leaflets, T wave inversion in the inferior basal leads on the electrocardiogram, annulus fibrosus disjunction, fibrosis of the papillary muscles and myocardium in the inferior basal wall of the left ventricle, determined by magnetic resonance imaging. resonance tomography and myocardial biopsies. In 2022, the European Heart Rhythm Association Expert Consensus presented risk stratification and treatment principles for patients with arrhythmic MVP, identifying low, intermediate and high-risk groups, and in 2024, the first meta-analysis of studies was performed to identify prognostic risk factors of arrhythmic MVP. The most significant predictors of arrhythmias included late gadolinium enhancement on magnetic resonance imaging, T-wave inversion on the electrocardiogram, prolapse of both mitral valve leaflets, and mitral annulus disjunction. When choosing treatment for patients with arrhythmic MVP, clinical characteristics are taken into account and a personalized approach is used to prevent sudden cardiac death and severe ventricular arrhythmias. As a rule, to prevent sudden cardiac death in patients with arrhythmic MVP, four treatment options are considered: medications (beta-blockers or non-dihydropyridine slow calcium channel blockers, a combination of a beta-blocker and flecainide, or amiodarone), radiofrequency ablation, surgical treatment of the mitral valve, implantable cardioverter — defibrillator (for primary or secondary prevention of sudden cardiac death).The rationale for surgical, electrophysiological, and/or therapeutic treatments depends on the specific rhythm disorder.

  • Open Access

    Coronary Microvascular Dysfunction: Epidemiology, Clinical Presentation, Diagnosis and Treatment

    by E. L. Trisvetova

    In a significant number of patients with symptoms of angina pectoris or myocardial infarction with ischemic changes in the myocardium, according to the results of instrumental research methods, there is no hemodynamically significant stenosis of the coronary arteries. In these cases, vasospastic angina or microvascular dysfunction is considered the cause of coronary heart disease. Coronary microvascular dysfunction is caused by several pathological mechanisms that cause structural and functional disorders in the microvascular bed of the heart. Clinical groups of coronary microvascular dysfunction include angina pectoris and myocardial ischemia without obstructive coronary artery disease (primary coronary microvascular dysfunction), in combination with coronary atherosclerosis, with myocardial damage and iatrogenic nature. Diagnostics of microvascular disorders is carried out on the basis of the results of non-invasive and invasive methods, which make it possible to clarify the nature of the changes and choose an effective nondrug and drug treatment. The prognosis for coronary microvascular dysfunction is poor, due to the development of cardiovascular complications and death, a high risk of disability, and a decrease in the quality of life of patients.


  • Open Access

    Postural Orthostatic Tachycardia Syndrome as a Manifestation of Post-COVID-19 Syndrome

    by E. L. Trisvetova

    The pandemic of coronavirus infection, the complex and insufficiently studied mechanisms of which cause disorders in the functions of many organs and systems of the body, has led to the emergence of new problems that are far from being resolved. Researchers note the difficulty in predicting the course of the disease and outcome due to the detection of many symptoms that arose at the height of the disease and persisted for 3-6 months after recovery. The term "post-COVID-19syndrome" has appeared, reflecting the condition of a patient who has undergone COVID-19, with a negative PCR test, and with symptoms lasting more than 12 weeks from the onset of the disease, which cannot be explained by an alternative diagnosis. Postural orthostatic tachycardia as a manifestation of the post-COVID-19syndrome has been described in young women who have undergone coronavirus infection of varying severity. In the case of the development of the syndrome of postural orthostatic tachycardia, the quality of life deteriorates, and the ability to work of patients is limited. There is no evidence base for drug therapy of postural tachycardia syndrome, in most cases empirical drug and non-drug methods of treatment are used.


  • Loeys – Dietz Syndrome: Clinical Presentation, Diagnosis

    by Е.л. Трисветова

    Издание посвящено всем направлениям кардиологии, рентгенэндоваскулярной, кардио- и сосудистой хирургии; публикует оригинальные исследования, клинические случаи, согласованные экспертные заключения, обзоры конференций и симпозиумов.

  • Open Access

    Primary hypertrophic osteoarthropathy

    by E. L. Trisvetova

    The article presents information about a rare hereditary disease – primary hypertrophic osteoarthropathy with autosomal dominant and autosomal recessive inheritance. Genetic heterogeneity is responsible for the clinical polymorphism of symptoms that appear in childhood and adolescence. Differential diagnosis should be carried out with secondary hypertrophic osteoarthropathy, which occurs in 90% of cases and is associated with malignant neoplasms, rheumatic diseases and other diseases. X-ray signs are of great importance to clarify the localization, extent and nature of bone lesions. There is no specific treatment for the disease.

  • Open Access

    Modern Concepts of Fibromuscular Dysplasia of the Coronary Arteries

    by E. L. Trisvetova

    Fibromuscular dysplasia of the coronary arteries is a rare non-atherosclerotic and non-inflammatory vascular lesion that is asymptomatic until serious complications develop: stenosis, dissection, rupture, sudden cardiac death. Since there are no long-term numerous clinical observations of patients with fibromuscular dysplasia of the coronary arteries, recommendations have not been developed for diagnosing and treating the disease, which often manifests with acute coronary syndrome. In 2014, the European Consensus was published, and in 2019, the first international consensus document on the diagnosis and treatment of fibromuscular dysplasia with lesions of vessels from different regions (renal, cerebrovascular, coronary, and others). The documents state that the development of fibromuscular dysplasia of the coronary arteries considers the participation of the PHACTR1 gene mutation and the transcriptional activity of the EDN1 gene, smoking, prolonged exertion of the vascular wall, and possibly female sex hormones. In the case of acute coronary syndrome, the most informative diagnostic method is computed tomography with angiography, which reveals a smooth narrowing of the lumen in the middle or distal section in the epicardial artery, often due to intramural hematoma, and also finds dissection, spasm, and tortuous vessel. Additional diagnostic methods ‒ intravascular ultrasound and optical coherence tomography allow differentiation of fibromuscular dysplasia with atherosclerosis of the coronary artery, vasculitis, and other diseases. The choice of treatment tactics for fibromuscular dysplasia of the coronary arteries depends on the severity of the clinical manifestations ‒ conservative medical treatment and interventional methods are used.


  • Open Access

    Diagnosis of isolated cardiac sarcoidosis

    by E. L. Trisvetova, O. A. Yudina, A. Z. Smolensky, E. D. Cherstvyi

    Heart involvement in sarcoidosis is diagnosed in vivo in 5-7%, at autopsy in 25% of cases as a manifestation of a systemic process and an isolated one. Difficulties in the diagnosis of isolated sarcoidosis are due to the absence of known causes of the disease and to the lack of specificity of clinical manifestations. The main symptoms include cardiac conduction and rhythm disturbances, cardiomyopathy with the development of heart failure, as well as pericardial involvement. Routine techniques (ECG, EchoCG, daily ECG monitoring) and imaging of the structures of the heart and its function evaluation (MRI, PET, and scintigraphy) are used in diagnosis. A set of clinical, instrumental, and histological data obtained at endomyocardial biopsy may suggest isolated cardiac sarcoidosis with the exception of other diseases.